Sign up now and fund within 24h to get A$10.
Claim It Now
Stake logo

OSL

Oncosil Medical Limited

1 day chart

About OSL

Oncosil Medical Limited (OSL, NeuroDiscovery Ltd) is an Australian based and ASX listed medical device company focused on localised treatments for patients with pancreatic and liver cancer. OncoSil's lead product, OncoSil is a first in class medical device with targeted radioactive isotope (Phosphorous-32), implanted directly into a patient's pancreatic tumors via an endoscopic ultrasound. This treatment, known as brachytherapy, is intended to deliver more concentrated and localized radiation.

Buy Australian shares starting with OSL. Invest today with a CHESS-sponsored investing platform!

Sector

Health Care

CEO

-

Industry

Life Sciences Tools & Services

Market Capitalisation

$18M

Price-earnings ratio

-0.80

Dividend yield

NaN%

High today

$0.01

Low today

$0.01

Open price

$0.01

52-week high

$0.03

52-week low

$0.01


Announcements





What does OncoSil Medical Limited (OSL) do?

Oh, nothing major, just trying to fight cancer. 

Headquartered in North Sydney, OncoSil Medical Limited is a medical device company focused on Interventional Oncology (IO), a minimally invasive form of oncology.

The company aims to make life easier for people enduring pancreatic cancer with OncoSil, its flagship brachytherapy device. OncoSil has been designed for implantation directly into a patient’s pancreatic tumours via an endoscopic ultrasound.

Compared to external beam radiotherapy, the OncoSil device can deliver higher doses of radiation while sparing damage to surrounding tissue and critical organs after implantation.

OncoSil Medical took its first step towards revenue generation in October 2020, when it achieved its first sale to a patient in New Zealand. However, COVID-19 disrupted the company’s commercialisation strategy. They're currently hard at work on progressing sales and adoption across Europe, the United States, the Middle East and Asia Pacific.

Is OncoSil Medical a profitable company?

No, OncoSil Medical is not a profitable company. 

The company reported revenue of A$213k in FY2021, but prior to this had not earned any revenue since FY2012. The company also recorded net losses between FY2012 and FY2021. In FY2019, FY2020 and FY2021 alone, the company’s net losses amounted to A$8.57m, A$4.26m and A$10.43m, respectively.

As of April 2022, the company holds A$6.6m of cash on its books.

Is OSL stock a buy?

Some investors believe it's a good time to buy OSL stock.

On 13 April 2022, OncoSil Medical announced the first commercial pancreas cancer treatment using the OncoSil device at The Hospital Universitario de Fuenlabrada in Madrid, Spain. The company also announced that ten more hospitals across Spain had been trained to use the OncoSil device. Off this news, the OSL stock price leapt almost 75% from A$0.04 to A$0.07.

However, other investors won’t go near OSL stock for now as the company remains unprofitable and has plenty more regulatory hoops to jump through.

Does OSL stock pay dividends?

OSL stock has no history of distributing dividends. The company has made no announcements to pay dividends this financial year or in the future.

Who owns OSL stock?

At 80.2% of the total float, the general public holds the majority of OSL stock. Individual insiders come second, holding 11.1%.

Some of OSL stock’s most significant owners include Netwealth Investments Ltd (3.04%), Rojo Nero Capital Pty Ltd (2.36%), Gregory Harris (1.98%), Roger Aston (1.6%) and Henderson Family Pty Ltd (1.18%).

Some individual insiders with significant holdings include Non-Executive Director Otto Buttula (3.79%), Global Sales and Marketing Director Michael Warrener (0.88%), CEO Nigel Lange (0.72%), Chairman of the Board Christopher Roberts (0.72%) and CFO Karl Pechmann (0.11%).

How do I buy OSL stock?

Stake offers a quick and easy way to purchase OSL shares – along with 2,000+ other Australian stocks and ASX ETFs – for a brokerage fee of only A$3.

Stake is a CHESS sponsored investing platform, meaning that when you buy ASX shares, you get a HIN (Holder Identification Number) and stocks are held in your name.

With Stake, you can be in the market in under 5 minutes, whether it's the ASX or Wall St. If you’re interested in building your portfolio by adding OSL, sign up today.


OSL FAQs

Yes, the Stake platform allows you to buy OSL shares and over 8,000 stocks and ETFs across the ASX and Wall St.

One share of Oncosil Medical Limited is valued at $0.01.

The ticker symbol for Oncosil Medical Limited is OSL.

To buy OSL stocks in Australia you'll need to open an account with an investing platform like Stake.
To do so follow these steps:
  1. Sign up in minutes, all you need is some I.D.
  2. Choose Stake AUS
  3. Deposit directly into your Stake wallet and you're ready to invest in OSL

The Oncosil Medical Limited 52-week high stock price is $0.03.

The Oncosil Medical Limited 52-week low stock price is $0.01.

As of 24/02/2024 Oncosil Medical Limited has a market cap of $18M.


Related Stocks

This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.


Stake logo
Over 7,000 5-star reviews
App Store logoGoogle Play logo

Subscribe to our free newsletters

By subscribing, you agree to our Privacy Policy.

Stakeshop Pty Ltd, trading as Stake, ACN 610105505, is an authorised representative (Authorised Representative No. 1241398) of Sanlam Private Wealth Pty Ltd (Australian Financial Services Licence No. 337927) ('Sanlam') and an authorised representative (Authorised Representative No. 1241398) of Airwallex Pty Ltd (Australian Financial Services Licence No. 487221) ('Airwallex'). Stake is not authorised by Airwallex under Airwallex’s AFSL to arrange for clients to be issued with securities as Airwallex is not authorised under its AFSL for this purpose. Stake is not authorised by Sanlam under Sanlam’s AFSL to arrange for clients to be issued with a non-cash payment facility as Sanlam is not authorised under its AFSL for this purpose. Stake SMSF Pty Ltd (‘Stake Super’) is not licensed to provide financial product advice under the Corporations Act. This specifically applies to any financial products which are established if you instruct Stake Super to set up a self managed super fund (‘SMSF’). When you sign up to Stake Super, you are contracting with Stake SMSF Pty Ltd who will assist in the establishment of a SMSF under a ‘no advice model’. You will also be referred to Stakeshop Pty Ltd to enable your trading account and bank account to be set up in order to use the Stake Website and/or App. Stakeshop Pty Ltd will also run marketing and promotions to you under. For more information about SMSFs, see our SMSF Risks page.The information on our website or our mobile application is not intended to be an inducement, offer or solicitation to anyone in any jurisdiction in which Stake is not regulated or able to market its services. At Stake and Stake Super, we’re focused on giving you a better investing experience but we don’t take into account your personal objectives, circumstances or financial needs. Any advice given by Stake is of a general nature only. As investments carry risk, before making any investment decision, please consider if it’s right for you and seek appropriate taxation and legal advice. Please view our Financial Services GuideTerms & ConditionsPrivacy Policy and Disclaimers  before deciding to invest on or use Stake or Stake Super. By using our website or service in any way, you agree to our Privacy Policy and Terms & Conditions. All financial products involve risk and you should ensure you understand the risks involved as certain financial products may not be suitable to everyone. Past performance of any product described on this website is not a reliable indication of future performance. Stake and Stake Super are registered trademarks in Australia.

Copyright © 2024 Stake. All rights reserved.